scholarly journals Training curriculum for European thoracic surgeons: a joint initiative of the European Society of Thoracic Surgeons and the European Respiratory Society

2020 ◽  
Vol 57 (3) ◽  
pp. 418-421
Author(s):  
Gilbert Massard ◽  
Nathalie Tabin ◽  
Lars Konge ◽  
Anna Elisabeth Frick ◽  
Hasan Batirel ◽  
...  
Keyword(s):  
European Society ◽  
Review Process ◽  
Task Force ◽  
Learning Opportunities ◽  
Assessment Tools ◽  
European Respiratory Society ◽  
Surgical Trainees ◽  
Technological Advances ◽  
External Expert ◽  
Level Of Knowledge

Abstract Because of the differing definitions of the margins of thoracic surgery as a specialty and the variability in the training curricula among European countries, the European Society of Thoracic Surgeons formed a task force to elaborate a consensual proposal. The first step comprised creating a harmonized syllabus that was completed and published in 2018. This publication presents a proposal for a curriculum upon which the task force and the external expert reviewers have agreed. The curriculum was developed by the task force: each module and item describe the expected level of knowledge, skills and attitudes to be attained by the participants; learning opportunities, assessment tools and minimal clinical exposures have been defined as well. Competence in terms of non-technical skills has been defined for each module according to the CanMEDS (http://www.royalcollege.ca/rcsite/canmeds/canmeds-framework-e) glossary. The different modules were subsequently submitted to an internal and an external review process and re-edited accordingly before final validation. The authors hope that this document will serve as a roadmap for both thoracic surgical trainees and mentors. It should further guide continuous professional development. However, evolving scientific and technological advances are expected to modify the diagnosis and treatment of diseases and disorders in the future and hence will mandate periodical revisions of the document.

scholarly journals ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma

2020 ◽  
Vol 55 (6) ◽  
pp. 1900953 ◽  
Author(s):  
Arnaud Scherpereel ◽  
Isabelle Opitz ◽  
Thierry Berghmans ◽  
Ioannis Psallidas ◽  
Markus Glatzer ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Malignant Pleural Mesothelioma ◽  
European Society ◽  
Radical Surgery ◽  
Task Force ◽  
Performance Status ◽  
Clinical Importance ◽  
Poor Performance Status ◽  
Pleural Mesothelioma ◽  
European Respiratory Society

The European Respiratory Society (ERS)/European Society of Thoracic Surgeons (ESTS)/European Association for Cardio-Thoracic Surgery (EACTS)/European Society for Radiotherapy and Oncology (ESTRO) task force brought together experts to update previous 2009 ERS/ESTS guidelines on management of malignant pleural mesothelioma (MPM), a rare cancer with globally poor outcome, after a systematic review of the 2009–2018 literature. The evidence was appraised using the Grading of Recommendations, Assessment, Development and Evaluation approach. The evidence syntheses were discussed and recommendations formulated by this multidisciplinary group of experts. Diagnosis: pleural biopsies remain the gold standard to confirm the diagnosis, usually obtained by thoracoscopy but occasionally via image-guided percutaneous needle biopsy in cases of pleural symphysis or poor performance status. Pathology: standard staining procedures are insufficient in ∼10% of cases, justifying the use of specific markers, including BAP-1 and CDKN2A (p16) for the separation of atypical mesothelial proliferation from MPM. Staging: in the absence of a uniform, robust and validated staging system, we advise using the most recent 2016 8th TNM (tumour, node, metastasis) classification, with an algorithm for pre-therapeutic assessment. Monitoring: patient's performance status, histological subtype and tumour volume are the main prognostic factors of clinical importance in routine MPM management. Other potential parameters should be recorded at baseline and reported in clinical trials. Treatment: (chemo)therapy has limited efficacy in MPM patients and only selected patients are candidates for radical surgery. New promising targeted therapies, immunotherapies and strategies have been reviewed. Because of limited data on the best combination treatment, we emphasise that patients who are considered candidates for a multimodal approach, including radical surgery, should be treated as part of clinical trials in MPM-dedicated centres.

scholarly journals ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma

2020 ◽  
Vol 58 (1) ◽  
pp. 1-24 ◽  
Author(s):  
Isabelle Opitz ◽  
Arnaud Scherpereel ◽  
Thierry Berghmans ◽  
Ioannis Psallidas ◽  
Markus Glatzer ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Malignant Pleural Mesothelioma ◽  
European Society ◽  
Radical Surgery ◽  
Task Force ◽  
Performance Status ◽  
Clinical Importance ◽  
Poor Performance Status ◽  
Pleural Mesothelioma ◽  
European Respiratory Society

Abstract The European Respiratory Society (ERS)/European Society of Thoracic Surgeons (ESTS)/European Association for Cardio-Thoracic Surgery (EACTS)/European Society for Radiotherapy and Oncology (ESTRO) task force brought together experts to update previous 2009 ERS/ESTS guidelines on management of malignant pleural mesothelioma (MPM), a rare cancer with globally poor outcome, after a systematic review of the 2009–2018 literature. The evidence was appraised using the Grading of Recommendations, Assessment, Development and Evaluation approach. The evidence syntheses were discussed and recommendations formulated by this multidisciplinary group of experts. Diagnosis: pleural biopsies remain the gold standard to confirm the diagnosis, usually obtained by thoracoscopy but occasionally via image-guided percutaneous needle biopsy in cases of pleural symphysis or poor performance status. Pathology: standard staining procedures are insufficient in ∼10% of cases, justifying the use of specific markers, including BAP-1 and CDKN2A (p16) for the separation of atypical mesothelial proliferation from MPM. Staging: in the absence of a uniform, robust and validated staging system, we advise using the most recent 2016 8th TNM (tumour, node, metastasis) classification, with an algorithm for pretherapeutic assessment. Monitoring: patient’s performance status, histological subtype and tumour volume are the main prognostic factors of clinical importance in routine MPM management. Other potential parameters should be recorded at baseline and reported in clinical trials. Treatment: (chemo)therapy has limited efficacy in MPM patients and only selected patients are candidates for radical surgery. New promising targeted therapies, immunotherapies and strategies have been reviewed. Because of limited data on the best combination treatment, we emphasize that patients who are considered candidates for a multimodal approach, including radical surgery, should be treated as part of clinical trials in MPM-dedicated centres.

Systemische Sklerose - eine systematische Übersicht

VASA ◽  
2011 ◽  
Vol 40 (1) ◽  
pp. 6-19 ◽  
Author(s):  
Klein-Weigel ◽  
Opitz ◽  
Riemekasten
Keyword(s):  
Pulmonary Hypertension ◽  
Systemic Sclerosis ◽  
Task Force ◽  
Systemische Sklerose ◽  
Systematische Übersicht ◽  
European Respiratory Society ◽  
High Association ◽  
Microscopic Features ◽  
European Society Of Cardiology ◽  
Genetic Burden

Due to its high association with Raynaud’s phenomenon systemic sclerosis (SSc) is probably the most common connective tissue disease seen by vascular specialists. In part 1 of our systematic overview we summarize classification concepts of scleroderma disorders, the epidemiologic and genetic burden, the complex pathophysiologic background, and the clinical features and the stage-dependent capillary microscopic features of SSc. Furthermore, we address the diagnostic recommendations propagated by the German Network for Systemic Sclerosis and the Task Force for Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology, the European Respiratory Society, and the International Society of Heart and Lung Transplantation.

Sign in / Sign up

Export Citation Format

Share Document